• Current cigarette smoking
ALLHAT

Major Exclusion Criteria
• MI, stroke, or angina within 6 months • Symptomatic CHF or ejection fraction <
35%
• Known renal insufficiency -creatinine ≥ 2 mg/dL
• Requiring diuretics, CCB, ACEI, or alpha blockers for reasons other than hypertension
ALLHAT
Sample Size Assumptions & Statistical Methods
• 83% power to detect 16% reduction in risk for primary outcome -99% power to detect 20% reduction with the observed event rate
• 2-sided α=.0178 (z=2.37) accounts for multiple comparisons
• Analysis according to "intent to treat"
• Cumulative event rates -Kaplan-Meier Follow until death or end of study (4-8 yr, ave 6 yr).
ALLHAT
Step 1 Treatment Protocol
Step Step 3 Agent:
Step Up Treatment Protocol
Safety Outcomes
• Angioedema Final Results Confirm That for Doxazosin / Chlorthalidone:
Biochemical Changes ALLHAT
• 20% ↑ risk of combined CVD
• 80% ↑ risk of heart failure
• 26% ↑ risk of stroke
• No difference for CHD or for total mortality
ALLHAT
Increased risk for some CV events for doxazosin in spite of lower total cholesterol and lower fasting glucose.
